Bausch + Lomb Corporation (BLCO)
12.22
0.82 (7.19%)
At close: Apr 14, 2025, 3:46 PM
7.19% (1D)
| Bid | 12.19 |
| Market Cap | 4.32B |
| Revenue (ttm) | 4.79B |
| Net Income (ttm) | -445M |
| EPS (ttm) | -0.9 |
| PE Ratio (ttm) | -13.58 |
| Forward PE | 22.07 |
| Analyst | Hold |
| Ask | 12.22 |
| Volume | 646,312 |
| Avg. Volume (20D) | 738,416 |
| Open | 11.63 |
| Previous Close | 11.40 |
| Day's Range | 11.76 - 12.22 |
| 52-Week Range | 10.46 - 21.69 |
| Beta | 0.54 |
About BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 6, 2022
Employees 13,500
Stock Exchange NYSE
Ticker Symbol BLCO
Website https://www.bausch.com
Analyst Forecast
According to 11 analyst ratings, the average rating for BLCO stock is "Hold." The 12-month stock price forecast is $18, which is an increase of 47.30% from the latest price.
Stock ForecastsNext Earnings Release
Bausch + Lomb Corporation is scheduled to release its earnings on Apr 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-9.52%
Bausch + Lomb shares are trading lower after the c...
Unlock content with
Pro Subscription
4 months ago
-12.06%
Bausch + Lomb shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $24 to $22.
